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Available online 13 December 2017Control of blood pressure (BP) in hypertension is recognized as a key measure in the management of cardiovas-
cular (CV) risk and is a cornerstone of preventive strategies. It is not defined, however, whether an initiation of
the antihypertensive treatment in the early stages of hypertension (such as prehypertension or high-normal
BP), may bring benefits for the long-term prevention of CV events. In addition, it has not been thoroughly
addressed the issue whether achievement of a prompt BP reduction in hypertensive patients may contribute
to reduce CV damage and events.
The aim of this article is to critically examine data from studies exploring these important questions. Our conclu-
sion is that the available evidence, though not very extensive, supports the prevailing benefits associated with
early BP control. We also discuss the therapeutic strategies to achieve early control of BP. Finally, we believe
that this aspect deserves to be more thoroughly addressed in upcoming international guidelines.
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(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
Hypertension
Prehyhpertension
Cardiovascular prevention
Early blood pressure control1. Introduction
Hypertension is a major cardiovascular (CV) risk factor and blood
pressure (BP) lowering therapies are able to reduce the incidence of
myocardial infarction, stroke, heart failure, CV and all-cause mortality
[1]. These findings have been recently confirmed by a large meta-
analysis conducted by Ettehad et al., including 68 randomized clinical
trials performed between 1966 and 2013 [2].
In view of the impressive growth of the number of hypertensive
patients (from 594 million in 1975 to 1.13 billion in 2015) [3], the
detection of elevated BP is a fundamental step of any CV prevention
strategy and its treatment has outstanding health benefits. Many
patients, however, are still unaware of their diagnosis, are untreated
or do not receive therapeutic regimens adequate to control BP within
normal limits [4].; CAD, coronary artery disease;
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land Ltd. This is an open access articlA recent analysis of data from European registries [5] has shown
that on average only 39% of hypertensive patients achieve an adequate
BP control. The proportion of patients reaching therapeutic targets,
however, is increasing worldwide (in Italy to about 61%), though
remaining unsatisfactory [6].
Multiple reasons may be advocated to explain persistent poor con-
trol of BP. Among these reasons, late or ineffective treatment, leading
to irreversible or difficult to reverse adaptations of the CV system, may
play a role.
Thus, among the strategies which may be adopted to obtain more
effective and long lasting BP reductions in hypertensive patients, one
possible approach, that has been repeatedly suggested in the past,
though never proved, relies on an early start of treatment and, even
more, on the early achievement of BP control.
In this regard, one real challenge is to unequivocally establish when
to initiate the treatment, if it is worth to pharmacologically treat all
grades of hypertension, and if it is possible to define a timeframe,
from the initiation of the treatment to the achievement of BP control,
which may eventually impact on CV outcomes. On this aspect,
guidelines have so far rather elusive, whereas a position seem to be
appropriate and needed.
We review here the literature on the evidence of the effects of
early and effective BP control in hypertension, keeping a focus also
on the targets to reach. With this approach we attempt to provide
physicians with the available data supporting the benefit of early BP
control.
We also discuss pharmacological interventions which may promote
early BP reduction in hypertensives.e under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Although several trials have contributed to support the concept that
prompt BP control may produce long-lasting BP reduction and decrease
the incidence of CV events, a precise and univocal definition of the
significance of early success and which early therapeutic strategies to
choose are still lacking.
The trial that is paradigmatically quoted to support the beneficial
effect of early BP control onmajor CV events is the Valsartan Antihyper-
tensive Long-term Use Evaluation (VALUE) study [7], which compared
the antihypertensive efficacy of the calcium channel blocker (CCB)
amlodipine with the angiotensin receptor blocker (ARB) valsartan.
Although the study was designed to assess the potential difference
between the two arms, a prespecified, wide post-hoc analysis compar-
ing the outcomes in “immediate” vs “non-immediate” responders was
performed, and it revealed very interesting and provocative data.
In fact, the achievement of systolic BP below 140 mm Hg within
6 months, defined as “immediate response”, independently on the
treatment adopted, was associated with a significant reduction of CV
outcomes when compared to “non-immediate responders” (those
who did not respond within the first 6 months). Even better results, in
terms of combined cardiac events, stroke and all-cause mortality, were
obtained in “immediate” responders, when identified with those
previously untreated patients with a systolic BP reduction of
10 mm Hg within the first month, or patients previously controlled
with other drugs, whose BP levels did not rise after the switch to the
medications adopted in the trial [7].
These results are consistentwith the findings of other large random-
ized trials.
Data derived from the Antihypertensive and Lipid-Lowering
treatment to prevent Heart Attack Trial (ALLHAT) suggest that the
achievement of BP control within 6 months is associated with a signifi-
cant reduction of stroke incidence. In this large study, non-immediate
responders had a higher incidence of combined CV disease, coronary
artery disease (CAD) and heart failure (HF) [8].
Also, the Authors of the Anglo-Scandinavian Cardiac Outcomes
Trial-BP Lowering Arm (ASCOT-BPLA), that assessed the superiority of
amlodipine-based vs. atenolol-base therapy, in reducing fatal and non-
fatal stroke, total CV events and procedures and all-cause mortality,
attributed this finding to the early BP lowering effect of amlodipine
during the first year of treatment [9].
Consistent with these results, the Study on Cognition and Prognosis
in the Elderly (SCOPE), which analyzed the effect of candesartan on
preventing major events in 4964 hypertensives, demonstrated the
benefits, in terms of reduction of stroke, of an early BP control within
the first 3 months of treatment [10]. The beneficial effect of fast BP
control, within 6 months but even more within 1-to-3 months, was
confirmed also in patients at high CV risk [11]. The results of these
studies are reported in Table 1. Indeed, they are strengthened by a
recent meta-analysis that has shown that achievement within a year
of a BP reduction of 10 mm Hg, for systolic values, and 5 mm Hg, forTable 1
Reduction of CV outcomes with Renin Angiotensin System blockers-based therapies achieving
Trial Number
of patients
Timeframe to reach
BP b140/90 mm Hg
Mean BP r
(mm Hg)
VALUE 14,400 6 months 12.3/6.1
ALLHAT 42,418 6 months 6.7/4.4
ASCOT-BPLA 19,342 1 year 21.9/11.7
SCOPE 4964 3 months 21.7/10.8diastolic, reduced coronary artery disease events by 22% and stroke by
41%, this effect being maintained over the long term [1].
Altogether, these findings consistently support that the benefit of BP
control is enhanced by rapidly achieving the response, and it can be
speculated that the faster is the goal achievement, the more sustained
is the CV protection.
If it might be true that earlier is better, evidence about the period of
time within which is critical to reach therapeutic BP targets are still
lacking.
3. BP control with drug treatment in mild hypertension and
prehypertension
It is also not clearwhether treating all grades of hypertensionmay be
considered as part of an early therapeutic strategy and the debate about
the need to start a prompt treatment in all patients at different levels of
CV risk remains.
Major international guidelines [12,13,14,15,16] vary about the
recommendations for drug treatment in grade 1 hypertension and in
patients at lower levels of CV risk.
The issue remains controversial and challenging nowadays, whereas
univocal recommendations have become a clinical need.
On the basis of the results of several studies and meta-analyses
[17,18,19,20,21], which definitely support a more intensive control of
systolic BP independently from CV risk levels, and regarding the new
lower thresholds of BP normality (130/80 mm Hg) advocated by the
recent North-American guidelines [22], the prompt initiation of
antihypertensive therapies may contribute to the achievement of
these proposed new therapeutic targets.
Current guidelines and risk prediction models take into account BP
levels only at the moment when the risk prediction is performed,
not considering the potential consequences of development of high BP
levels earlier in life, and of the cumulative effect linked to the long-
term exposure to high BP and to the associated risk over time.
Analyses from the Framingham Heart Study [23], the REGARDS
study (Reasons for Geographic and Racial Differences in Stroke) [24]
and the MESA (Multi-Ethnic Study of Atherosclerosis) [25] have
shown that individuals with higher BP levels, even below the diagnostic
threshold for hypertension, have an increased prospective risk of
clinical and subclinical CV disease, especially when lifetime risk is
estimated.
Loria et al. have demonstrated that BP levels in young adulthood
better predict development of coronary calcium score 15 years later
[26].
In the CARDIA study, adults with a longer exposure to higher BP
showed an increased risk of organ damage, atherosclerosis, kidney
disease and myocardial infarction (MI). These individuals may indeed
have a low short-term, but a high lifetime, CV risk [19].
On the basis of these reports and in view of the direct relation
between BP levels and CV events that have been demonstrated by
several epidemiological studies, starting from values of 115/early BP control (3–12 months) in large randomized control trials.
eduction CV outcomes Reduction of CV outcomes
in early BP response (%)
Total CV events 12
Stroke 17
All-cause death 10
Stroke 33
Total CV events 21
All cause death 16
HF 22
Fatal and non-fatal stroke 23
Total CV events 16
All-cause mortality 11
Fatal and non-fatal stroke 24
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tensive treatment, also in subjects with grade 1 hypertension or high-
normal BP, may be associated with long-term clinical benefits [27].
A recent meta-analysis of the BP Lowering Treatment Trialists'
Collaboration (BPLTTC) has analyzed data of grade 1 hypertensive
patients with low-to-moderate CV risk from 10 randomized clinical
trials. Pharmacological treatment was associated with a significant
reduction of CAD, stroke and CV and all-cause mortality, independently
from concomitant risk factors and baseline BP levels [28] (Fig. 1).
These data have been confirmed also in another meta-analysis of
68 trials, involving N245,000 individuals at different levels of risk,
ranging from low-to-moderate to very-very high. This shows that
relative reductions of all outcomes are comparable among groups,
with absolute risk reductions increasing proportionally to the level of
CV risk. The proportional decrease in disease events, for a given BP
reduction, was the same irrespective of BP before treatment, thus
supporting the advantages of the treatment also in grade 1 hyperten-
sives [29]. Although the absolute beneficial effect of anti-hypertensive
treatment is greater in the highest risk categories, the residual risk of
major events, that occur even when adequate BP control is achieved,
is proportional to the estimated baseline CV risk and the greatest suc-
cess is reached in low-to-moderate risk patients, before the occurrence
of overt organ damage [1,11].
Another challenging question is whether the incidence of
hypertension can be decreased starting medications in subjects
with prehypertension (systolic of 120–139 mm Hg or diastolic of 80–
89 mm Hg), or high-normal BP (130–139/85–90 mm Hg) and if the
residual risk can be further reduced in these categories.
Several studies have shown that about 60% of untreated pre-
hypertensive patients will develop hypertension within 4 years, with a
3-fold greater risk than in subjects with BP values b120/80 mm Hg.
The role of pharmacological therapies in preventing the onset of
hypertension has been investigated in the TRial Of Preventing HYper-
tension (TROPHY), which underlined the insufficiency of educational
intervention in most of patients with BP above optimal threshold and
other concomitant risk factors, and suggested that a long-term pharma-
cological strategy initiated in the prehypertensive stage may provide
protective effect [30].
Several studies have demonstrated that prehypertensive individuals,
who often present other associated CV risk factors, have an increased
risk profile compared to those with optimal BP b120/80 mm Hg, inde-
pendently of progression to hypertension, even if major events may
occur many years later than in patients with established hypertension.
This goes along with the historical meta-analysis of Collins et al.,
showing that the risk of stroke and myocardial infarction progressively
increases starting from 115 mm Hg systolic BP for each decade of ageFig. 1. CV outcomes in treated vs. untreated patients with mild hypertension. Modified
from Ref 28.[31]. The rate of CV events is increased also in “stage 1” prehypertension
(BP 120–129/80–84 mm Hg), although their incidence is halved
compared to individuals with “stage 2” hypertension. In absolute
terms, the estimated rate of CV events is 1.0%/year in the high-normal
BP range, compared to 0.5%/year in persons with normal BP.
In the Strong Heart Study, the incidence of CV disease was 1.8 fold
higher in the prehypertensive cohort and even higher (2.1 fold) in
patients with high-normal BP levels, even after demographic adjust-
ments [32].
Thompson et al. have investigated the effects of BP lowering therapy
in patients with normal or high normal BP levels, without a background
of antihypertensive treatment, on fatal and nonfatal CV events in a large
cohort of 64,162 patients from 25 randomized clinical trials. Antihyper-
tensive treatment was able to reduce the incidence of stroke, MI, HF, CV
and all-cause mortality [33].
Thus, prehypertension needs to be clinically monitored and eventu-
ally treated especially when high total risk is estimated. Therefore,
prevention strategies need to be carefully considered and extended to
all CV risk categories.
Since CV disease often reflects a multifactorial disorder, additional
risk factors often cluster in hypertensive patients, with a greater preva-
lence compared to normotensive individuals, as documented by several
epidemiological studies.
The coexistence of several risk factor exponentially increase the
incidence of major CV events, 6-fold greater in hypertensive men with
elevated cholesterol concentrations and smoking habit compared
to subjects with high BP nonsmokers with normal cholesterol levels
[34,35].
Due to the continuum of CV risk, it is reasonable to postulate that
earlier BP treatment, by reducing the cumulative exposure to high BP
levels, may contribute to prevent, or at least delay, the development of
end organ damage and may abolish, in the absence of other risk factors,
or at least reduce, if additional risk factors are present, the excess of CV
risk.
4. Therapeutic strategies for early BP control
For patients without a compelling indication for a specific class of
antihypertensive medication, according to current Guidelines [15,22],
physicians may start and maintain therapies with diuretics, beta-
blockers, CCBs, angiotensin-converting enzyme inhibitors and ARBs,
either as monotherapy or in combinations. However, different classes
provide different CV protection, independent of BP reduction, as
paradigmatically observed in some large trials [36,37].
In addition, it must be considered that a single-drug therapeutic
regimen is often insufficient to reach an early BP control, especially in
patients with higher baseline BP levels and other CV risk factors.
Several studies have demonstrated that initiationwith a dual combi-
nation, especially as a single-pill, is associated with a faster and greater
antihypertensive effect and a more persistent BP control at one-year
follow-up. An adequate BP control was more likely to be obtained
during the first year of therapy in patients initially treated with single-
pill combination than in those who began with free combinations or
monotherapy, with a better adherence and a greater persistence on
therapy [38,39,40].
Due to their favourable role in prevention of major CV events, and
to the good tolerability profile and to their pathophysiological synergies
with other pharmacological classes, drugs blocking the Renin-
Angiotensin-System, e.g. ARBs are frequently used as first-line therapy
and represent the basis of single pill combinations.
In particular, among available ARBs, there is growing evidence of the
higher efficacy of the long-lasting compounds, such as olmesartan
medoxomil, in achieving an early and sustained BP control.
Several studies have demonstrated that a greater percentage of
patients treated with olmesartan achieved BP targets, compared to
those who received initial doses of losartan, candesartan, valsartan
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ambulatory systolic and diastolic BP levels, already after 1,2, 4 and
8 weeks of therapy, both in naïve and previously treated patients and
independently from the grade of hypertension [41,42,43,44,45,46]
(Fig. 2).
Olmesartan has a greater efficacy than irbesartan, valsartan, losartan
and candesartan in reducing 24-h ambulatory systolic and diastolic BP
after 8 weeks treatment [39]. The proportion of patients treated with
olmesartan, who were normalized, was higher compared to those
who received losartan 50 mg, irbesartan 150 mg or valsartan 80 mg,
with a greater reduction of both systolic and diastolic BP [43].
These data have been confirmed by a large meta-analysis of 22 ran-
domized controlled trials which assessed the better antihypertensive
efficacy of olmesartan, in the absence of an increased risk of adverse
events [47].
The efficacy and safety profile of olmesartan has been demonstrated
also in combination therapies, with both CCs and diuretics, producing
faster and lager reductions in both systolic and diastolic BP compared
to associations based on irbesartan, telmisartan and valsartan [48].
In a treat-to-goal study conducted by Volpe et al., the triple-
combination therapy of olmesartan, amlodipine and HCTZ resulted in
incremental reduction of BP and in a significantly higher percentage of
therapeutic goal achievement compared to the dual combinations [49].
Similar results have been obtained in the BP CRUSH and the TRINITY
(the TRIple therapy with olmesartan medoxomil, amlodipine, and
hydrochlorothiazide in hyperteNsIve patients studY) trials, which
have demonstrated that both seated systolic and diastolic BP reductions
were faster and greater with triple combination therapy of olmesartan,
amlodipine and HCTZ, compared with those of dual combination
therapies [50,51]. In all these studies the rate of early responders largely
exceeded 60%, ranging on 67.5% in the presence of a rate of 1.2% of
adverse effects [52].
Of course, other long-lasting compounds in the class, such as
azilsartan, appear to have a similar effective profile in effectively reduc-
ing BP in hypertensives in a fast and sustained fashion.
The use of fixed-dose combination therapies represents a very
attractive strategy for improving BP control and represents today one
of the key elements for a successful large-scale hypertension program
with the aim of obtaining BP control in the large majority of hyperten-
sive patients, as well as higher levels of adherence and persistence of
the treatment [53]. In this view, a platform approach has been proposed
to help physicians in making the most appropriate choice, with thera-
pies founded on single-pill fixed dose combination of two or threeFig. 2. Different speed of BP reductions of different drugs at initial dosages within the
same class (ARBs).drugs, on the basis of grade of hypertension, concomitant risk factors
and organ damage and comorbidities [54,55].
Since initial treatment with two or more agents is associated not
only with an earlier and more effective antihypertensive control, but
also to more lasting results in terms of CV prevention, it is desirable
that clinicians consider more and more frequently this strategy as
first-line choice, especially in high or very-high risk categories.
Accordingly, international guidelines are progressively moving
towards an extensive implementation of single-pill combination
therapies in the clinical practice to achieve early and sustained control
of BP.
5. Conclusions
Early start of an antihypertensive treatment is associated with a
more effective and more lasting BP control and may reduce the impact
of cumulative CV risk exposure. In addition, a fast achievement of BP
control univocally leads to greater CV benefits. In this regard, more
effective compounds within the same class, and even more, the early
use of fixed-combination therapies, especially in single pill, can be
preferred to achieve the objective.
Further perspective studies in this area are required and international
guidelines will need to address this issue.
The Latin poet Horace wrote that “Dimidium facti, qui coepit, habet”:
“A good start is half of the battle”: this appears to be suitable for a better
hypertension management.
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